Mesoblast Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MESO research report →
Range $39 – $39
Price Chart
About the company
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders.
- CEO
- Silviu Itescu
- IPO
- 2010
- Employees
- 108
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on MESO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.41B
- P/E
- -25.28
- Fwd P/E
- 48.15
- PEG
- -0.36
- P/S
- 11.86
- P/B
- 2.56
- EV/EBITDA
- -34.45
- Div Yield
- 0.00%
- Gross Margin
- 78.30%
- Op Margin
- -96.11%
- Net Margin
- -46.79%
- ROE
- -10.06%
- ROIC
- -16.74%
Latest fiscal year · YoY change
- Revenue
- $120.79M+602.3%
- Gross Profit
- $101.58M+741.7%
- Op Income
- $-51,501,040
- Net Income
- $-57,756,862+43.5%
- EPS
- $-0.45+46.7%
- OCF Growth
- +12.3%
- FCF Growth
- +11.8%
- 52W High
- $21.50
- 52W Low
- $10.87
- 50D MA
- $13.96
- 200D MA
- $15.10
- Beta
- 0.81
- RSI (14)
- 33
- Avg Volume
- 240.25K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Mesoblast said FY2026 marked its transition to a commercial company, with RYONCIL driving $115 million of net revenue and management pointing to further growth from pediatric and adult label expansion plus late-stage pipeline readouts.· August 26, 2026
- RYONCIL generated $115 million of net revenue in FY2026, with fourth-quarter net revenue of $36 million.
- Gross profit on total sales, excluding amortization expenses, was $110 million, and net loss after taxes fell 44% to $57.5 million.
- Cash and balance sheet improved: year-end cash was $103 million, net cash usage was $43.8 million, and second-half cash burn fell to $13.4 million versus $50 million a year earlier.
- Management highlighted adult acute GvHD as a major expansion opportunity, with a randomized 180-patient trial enrolling across more than 40 U.S. sites and interim analysis expected in 4Q 2027.
- The chronic low back pain Phase 3 trial has completed treatment of all 350 patients, with readout expected in the second half of calendar 2027 and possible approval in 2028.
Mesoblast reported FY2026 net revenue of $115 million, including fourth-quarter net revenue of $36 million. Gross profit on total sales, excluding amortization expenses, was $110 million. Product development costs were $17.3 million, continued R&D investment in Phase 3 programs was roughly $21.2 million, and sales and marketing expense increased by about $18 million. Net loss after taxes improved 44% to $57.5 million. The company ended the year with $103 million of cash, had net cash usage of $43.8 million, and second-half cash burn was $13.4 million versus $50 million in the prior-year period. For guidance, management said it expects double-digit growth in the coming 12-month period for RYONCIL and expects fiscal 2027 cash burn to be less than fiscal 2026, but declined to give a specific quarter for cash flow positivity.
Silviu Itescu framed FY2026 as the company’s transition from an R&D business to a commercial one, emphasizing that RYONCIL is now the only FDA-approved mesenchymal stromal cell product and that its revenues are being reinvested into Phase 3 programs and manufacturing. He repeatedly pointed to what he called Mesoblast’s “moat,” including more than 1,100 patents and patent applications, FDA alignment, and scale-up/manufacturing know-how. His tone was constructive and expansion-oriented, with focus on pediatric and adult GvHD, Duchenne muscular dystrophy, chronic low back pain, and inflammatory heart failure.
James O’Brien focused on the financial leverage coming from commercial revenue and tighter spend. He cited $115 million of net revenue, $17.3 million of product development costs, $21.2 million of Phase 3 R&D investment, and about $18 million of additional sales and marketing spend to support RYONCIL. He said net loss after tax declined 44% to $57.5 million, cash was $103 million at year-end, net cash usage was $43.8 million, and second-half cash burn improved to $13.4 million from $50 million a year earlier. He also noted the $125 million credit facility at 8% interest with no principal amortization for five years, and said fiscal 2027 cash burn should be lower than fiscal 2026.
Analysts focused on how quickly RYONCIL could grow, especially in the pediatric GvHD business, and what would drive a broader launch in Duchenne muscular dystrophy. Management said it expects double-digit growth in the next 12 months, but did not give precise revenue guidance, and explained Duchenne was selected because earlier treatment in younger children may better address inflammation than later-stage approaches. Questions also centered on the adult GvHD study; management said the 180-patient trial is powered around 85% to 90%, interim analysis is expected when about 57% of patients are enrolled, and both the full study and interim route have been vetted with the FDA for an sBLA filing. On financing, management said it would keep options open but believes current cash and long-term debt structure are sufficient to support planned programs.
The call suggested RYONCIL is gaining commercial traction, with $115 million in first full-year revenue, broad reimbursement coverage, and more than 50 centers onboarded. Management also described several real catalyst paths: adult GvHD expansion, Duchenne development, and a completed 350-patient back-pain Phase 3 trial that could support a large future launch.
The company is still not profitable, posting a $57.5 million net loss, and management would not commit to a quarter for cash flow positivity. Several growth plans depend on successful trial outcomes and regulatory interactions, including adult GvHD, Duchenne, chronic low back pain, and heart failure, so execution and FDA outcomes remain key risks. Management also said it is early in the year and did not provide specific fiscal 2027 revenue or cash-flow guidance beyond double-digit RYONCIL growth and lower cash burn.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 64.1%
- Shares Outstanding
- 129.85M
- Float Shares
- 83.20M
of shares held by institutions
78 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 851.41K | ▲ 132.80K |
| Blackrock, Inc. | 744.36K | ▲ 80.08K |
| Goldman Sachs Group Inc | 409.19K | ▲ 13.58K |
| Susquehanna International Group, Llp | 350.09K | ▼ 107.66K |
| Bnp Paribas Asset Management Holding S.A. | 259.70K | 0 |
| Ubs Group AG | 197.18K | ▼ 2.87K |
| Arax Advisory Partners | 175.32K | ▲ 7.30K |
| Keel Point, LLC | 174.26K | ▲ 174.26K |
| Citadel Advisors LLC | 154.09K | ▲ 154.09K |
| Group One Trading LLC | 132.24K | ▲ 88.21K |
| Bank Of America Corp | 100.00K | 0 |
| M&G PLC | 59.10K | 0 |
Held by 20 ETFs
Biggest fund positions in MESO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 23, 25 | OBRIEN JAMES MICHAEL | other | 650,000 |
| Mar 18, 26 | COBLEY LYNETTE ELIZABETH | other | 0 |
| Mar 18, 26 | COBLEY LYNETTE ELIZABETH | other | 0 |
| Mar 18, 26 | COBLEY LYNETTE ELIZABETH | other | 0 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 5,000 |
| Apr 9, 26 | George Gregory | buy | 10,000 |
| Apr 9, 26 | George Gregory | buy | 5,240 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MESO coverage
Recent articles, reports, and earnings notes.
No research on MESO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MESO report →Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award
globenewswire.com · Nov 19
Mesoblast Showcased at ASX Premier Investor Day Event
globenewswire.com · Nov 15
Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout
marketbeat.com · Nov 12
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
globenewswire.com · Nov 4
Mesoblast Board Changes
globenewswire.com · Nov 1
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
globenewswire.com · Oct 28
Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain
seekingalpha.com · Oct 19
Mesoblast (NASDAQ:MESO) Stock Price Breaks Below 50 Day Moving Average – Should You Sell?
defenseworld.net · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.